secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2026-04-03T23:59:59+00:00
Accession:  0001628280-26-023699
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience appoints John Sharp as CFO and reprices underwater options to $0.6150
--------------------------------------------------------------------------------

- John P. Sharp appointed CFO effective March 31, 2026; services via Lohman & Associates at $25,600/month for up to 64 hours.
- Board approved repricing of 2,420,978 outstanding options held by full-time employees to $0.6150/share (closing price on repricing date).
- Repriced options previously had exercise prices ranging from $1.055 to $14.56; include 1,103,959 options held by CEO Punit Dhillon and 396,295 held by COO Tuan Diep.
- Option repricing intended to retain and motivate eligible participants without additional dilution or cash compensation.
- Master Services Agreement with Lohman & Associates entered; Sharp will serve as principal financial and accounting officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000162828026023699/0001628280-26-023699-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000162828026023699/skye-20260331.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-023699

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer